drugset
drugset / Trial / NCT05681819

A Study of SHR-1707 With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease

NCT05681819 ↗

Phase 1 Completed 33 enrolled Shanghai Hengrui Pharmaceutical Co., Ltd.
RandomizedParallel-groupTriple-blindOther

Summary

This study aims to evaluate the safety, tolerability and pharmacodynamics of intravenous administration of SHR-1707 In patients with mild cognitive impairment due to Alzheimer's Disease or mild Alzheimer's Disease.

Timeline

Start
2023-02-17
Primary completion
2024-05-18
Completion
2025-08-13

Drugs

EvaluationDrugModalityDoseRoute
Subject SHR-1707 Monoclonal antibody — Intravenous

Indications

Alzheimer disease